Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Munster – page 32

692 clinical trials in Munster, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Munster at a glance
692
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

692 trials in Munster

Open in trial search

Choroidal neovascularisation

Not recruiting

Faricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Faricimab
  • Sponsor:F. Hoffmann-La Roche AG

Obesity

Not recruiting

A study to evaluate the efficacy and safety of zenagamtide in people with obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Sponsor:Novo Nordisk A/S

Colitis ulcerative

Not recruiting

A study to evaluate the efficacy and safety of vixarelimab in patients with moderate to severe ulcerative colitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Genentech Inc.

Small cell lung cancer extensive stage

Not recruiting

Study of Tarlatamab and Durvalumab compared to Durvalumab alone for patients with extensive stage small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Amgen Inc.

Systemic lupus erythematosus

Not recruiting

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Hormone-dependent prostate cancer+1

Not recruiting

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Dementia Alzheimer's type

Not recruiting

Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:F. Hoffmann-La Roche AG

Dementia Alzheimer's type

Not recruiting

A study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:F. Hoffmann-La Roche AG

Prostate cancer

Not recruiting

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Amgen Inc.

Squamous cell carcinoma of head and neck

Not recruiting

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:BioNTech SE

Ovarian cancer

Not recruiting

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tuvusertib
  • Sponsor:Merck Healthcare KGaA

Type 2 diabetes mellitus

Not recruiting

Study comparing cagrilintide and semaglutide versus tirzepatide in people with type 2 diabetes taking metformin or SGLT2 inhibitor

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Munster

What the registry says about research in the country

01 Oncology & Hematology

Advanced research focusing on lymphoma treatments and innovative therapies for breast cancer and lung cancer. Studies include evaluations of new combinations of targeted therapies and immunotherapy approaches.

  • Diffuse Large B-Cell Lymphoma
  • Advanced Breast Cancer
  • Non-Small Cell Lung Cancer
  • Acute Myeloid Leukemia

Several trials are exploring novel treatment combinations and maintenance therapies for various blood cancers.

02 Metabolic & Cardiovascular Disorders

Comprehensive studies addressing obesity management and cardiovascular disease prevention. Research includes innovative approaches for weight management and heart failure risk reduction.

  • Obesity Treatment
  • Type 2 Diabetes
  • Heart Failure Prevention
  • Cardiovascular Risk Management

Multiple trials are investigating new therapeutic options for weight management and cardiovascular health improvement.

03 Dermatology & Immunology

Innovative research in treating chronic skin conditions including plaque psoriasis and hidradenitis suppurativa. Studies focus on novel biological therapies and targeted treatments.

  • Moderate to Severe Plaque Psoriasis
  • Hidradenitis Suppurativa
  • Chronic Rhinosinusitis

Trials are evaluating next-generation treatments for inflammatory skin conditions and immune-mediated disorders.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.